Tue, Jan 27, 2015, 4:52 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

  • cacrawfish cacrawfish Dec 21, 2005 7:02 PM Flag

    previous HCV trial

    Congrats SCLN shareholder, there is still along way to go, but todays news indicates, again, Zand is providing some help.

    Thinking back on the last failed HCV trial and where things went wrong, I wanted to highlight the following paper.

    Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.

    Cleve Clin J Med. 2004 May;71 Suppl 3:S13-6

    �No therapy has been shown to yield SVR in patients who do not respond to pegylated interferon and ribavirin.�


    For the next trial you would have the best chance of success if the peg-IFN/ribav patients that were completely non-responders were removed from the cohort. You want the people that showed an initial response but relapsed. There are some patients that don�t show any drop in viral levels during the first line therapy; they should be removed.

    The other factors:

    �Factors associated with sustained virologic response (SVR) following retreatment include prior treatment with interferon monotherapy, HCV genotype 2 or 3, a low serum HCV RNA level, and the absence of cirrhosis. Fewer than 6% of nonresponders who were previously treated with interferon and ribavirin and who have cirrhosis, genotype 1, and a high viral load achieve SVR following retreatment with pegylated interferon and ribavirin.�

    Good Luck.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
7.370.00(0.00%)4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.